

| | | |
|------------|--|--|
| STN | Medicínske laboratóriá Aplikácia manažerstva rizík pre medicínske laboratóriá (ISO 22367: 2020) | STN EN ISO 22367 85 5009 |
|------------|--|--|

Medical laboratories - Application of risk management to medical laboratories (ISO 22367:2020)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 06/20

Obsahuje: EN ISO 22367:2020, ISO 22367:2020

Oznámením tejto normy sa ruší
STN P CEN ISO/TS 22367 (85 5009) z mája 2010

130913

EUROPEAN STANDARD

EN ISO 22367

NORME EUROPÉENNE

EUROPÄISCHE NORM

March 2020

ICS 11.100.01

Supersedes CEN ISO/TS 22367:2010

English Version

Medical laboratories - Application of risk management to medical laboratories (ISO 22367:2020)

Laboratoires de biologie médicale - Application de la
gestion des risques aux laboratoires de biologie
médicale (ISO 22367:2020)

Medizinische Laboratorien - Fehlerverringierung durch
Risikomanagement und ständige Verbesserung (ISO
22367:2020)

This European Standard was approved by CEN on 7 February 2020.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

EN ISO 22367:2020 (E)

| Contents | Page |
|-------------------------------|-------------|
| European foreword..... | 3 |

European foreword

This document (EN ISO 22367:2020) has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by September 2020, and conflicting national standards shall be withdrawn at the latest by March 2023.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes CEN ISO/TS 22367:2010.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 22367:2020 has been approved by CEN as EN ISO 22367:2020 without any modification.

INTERNATIONAL STANDARD

ISO
22367

First edition
2020-02

Medical laboratories — Application of risk management to medical laboratories

*Laboratoires de biologie médicale — Application de la gestion des
risques aux laboratoires de biologie médicale*



Reference number
ISO 22367:2020(E)

© ISO 2020

**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2020

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

| | Page |
|---|-----------|
| Foreword | v |
| Introduction | vi |
| 1 Scope | 1 |
| 2 Normative references | 1 |
| 3 Terms and definitions | 1 |
| 4 Risk management | 8 |
| 4.1 Risk management process..... | 8 |
| 4.2 Management responsibilities..... | 9 |
| 4.3 Qualification of personnel..... | 10 |
| 4.4 Risk management plan..... | 10 |
| 4.4.1 General..... | 10 |
| 4.4.2 Scope of the plan..... | 11 |
| 4.4.3 Contents of the plan..... | 11 |
| 4.4.4 Revisions to the plan..... | 11 |
| 4.4.5 Risk management documentation..... | 12 |
| 5 Risk analysis | 12 |
| 5.1 General..... | 12 |
| 5.2 Risk analysis process and documentation..... | 13 |
| 5.3 Intended medical laboratory use and reasonably foreseeable misuses..... | 13 |
| 5.4 Identification of characteristics related to safety..... | 13 |
| 5.5 Identification of hazards..... | 13 |
| 5.6 Identification of potentially hazardous situations..... | 14 |
| 5.7 Identification of foreseeable patient harms..... | 14 |
| 5.8 Estimation of the risk(s) for each hazardous situation..... | 14 |
| 6 Risk evaluation | 15 |
| 6.1 Risk acceptability criteria..... | 15 |
| 6.2 Risk evaluation process..... | 16 |
| 7 Risk control | 16 |
| 7.1 Risk control options..... | 16 |
| 7.2 Risk control verification..... | 17 |
| 7.3 Role of standards in risk control..... | 17 |
| 7.4 Role of IVD medical devices in risk control..... | 17 |
| 7.5 Risks arising from risk control measures..... | 17 |
| 7.6 Residual risk evaluation..... | 17 |
| 8 Benefit-risk analysis | 18 |
| 9 Risk management review | 18 |
| 9.1 Completeness of risk control..... | 18 |
| 9.2 Evaluation of overall residual risk..... | 18 |
| 9.3 Risk management report..... | 19 |
| 10 Risk monitoring, analysis and control activities | 19 |
| 10.1 Surveillance procedure..... | 19 |
| 10.2 Internal sources of risk information..... | 20 |
| 10.3 External sources of risk information..... | 20 |
| 10.4 Immediate actions to reduce risk..... | 20 |
| Annex A (informative) Implementation of risk management within the quality management system | 22 |
| Annex B (informative) Developing a risk management plan | 32 |
| Annex C (informative) Risk acceptability considerations | 34 |

ISO 22367:2020(E)

| | |
|---|-----------|
| Annex D (informative) Identification of characteristics related to safety | 37 |
| Annex E (informative) Examples of hazards, foreseeable sequences of events and hazardous situations | 44 |
| Annex F (informative) Nonconformities potentially leading to significant risks | 52 |
| Annex G (informative) Risk analysis tools and techniques | 60 |
| Annex H (informative) Risk analysis of foreseeable user actions | 65 |
| Annex I (informative) Methods of risk assessment, including estimation of probability and severity of harm | 69 |
| Annex J (informative) Overall residual risk evaluation and risk management review | 75 |
| Annex K (informative) Conducting a benefit-risk analysis | 77 |
| Annex L (informative) Residual risk(s) | 80 |
| Bibliography | 81 |

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

This first edition cancels and replaces (ISO/TS 22367:2008) which has been technically revised. [It also incorporates the Technical corrigendum ISO/TS 22367:2008/Cor.1:2009.]. The main changes compared to the previous edition are as follows:

- Change in title to indicate this document focusses on the complete risk management cycle for all processes in the medical laboratory. The part on continual improvement is left out;
- The numbering of the clauses is in accordance with the formal risk management process as indicated in [Figure 1](#);
- The content is as far as possible in agreement with the approach used in ISO 14971 Medical devices -Application of risk management to medical devices;
- The relation with ISO 15189:2012 is indicated in Annex A in which [Figure A.1](#) provides a flow chart which indicates how to apply risk management in the laboratory;
- Addition of 10 new annexes, all informative, providing valuable information about the different processes in the risk management cycle without demanding more than justified for the specific purpose;
- [Annex F](#) provides an extensive list of aspects which could be considered as source for risks in the different types of medical laboratories.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

ISO 22367:2020(E)

Introduction

This document provides medical laboratories with a framework within which experience, insight and judgment are applied to manage the risks associated with laboratory examinations. The risk management process spans the complete range of medical laboratory services: pre-examination, examination and post-examination processes, including the design and development of laboratory examinations.

ISO 15189 requires that medical laboratories review their work processes, evaluate the impact of potential failures on examination results, modify the processes to reduce or eliminate the identified risks, and document the decisions and actions taken. This document describes a process for managing these safety risks, primarily to the patient, but also to the operator, other persons, equipment and other property, and the environment. It does not address business enterprise risks, which are the subject of ISO 31000.

Medical laboratories often rely on the use of in vitro medical devices to achieve their quality objectives. Thus, risk management has to be a shared responsibility between the IVD manufacturer and the medical laboratory. Since most IVD manufacturers have already implemented ISO 14971:2007, "Medical devices -Application of risk management to medical devices," this standard has adopted the same concepts, principles and framework to manage the risks associated with the medical laboratory.

Activities in a medical laboratory can expose patients, workers or other stakeholders to a variety of hazards, which can lead directly or indirectly to varying degrees of harm. The concept of risk has two components:

- a) the probability of occurrence of harm;
- b) the consequence of that harm, that is, how severe the harm might be.

Risk management is complex because each stakeholder may place a different value on the risk of harm. Alignment of this standard with ISO 14971 and the guidance of the Global Harmonization Task Force (GHTF) is intended to improve risk communication and cooperation among laboratories, IVD manufacturers, regulatory authorities, accreditation bodies and other stakeholders for the benefit of patients, laboratories and the public health.

Medical laboratories have traditionally focused on detecting errors, which are often the consequence of use errors during routine activities. Use errors can result from a poorly designed instrument interface, or reliance on inadequate information provided by the manufacturer. They can also result from reasonably foreseeable misuse, such as intentional disregard of an IVD manufacturer's instructions for use, or failure to follow generally accepted medical laboratory practices. These errors can cause or contribute to hazards, which may manifest themselves immediately as a single event, or may be expressed multiple times throughout a system, or may remain latent until other contributory events occur. The emerging field of usability engineering addresses all of these 'human factors' as preventable 'use errors.' In addition, laboratories also have to contend with occasional failures of their IVD medical devices to perform as intended. Regardless of their cause, risks created by device malfunctions and use errors can be actively managed.

Risk management interfaces with quality management at many points in ISO 15189, in particular complaint management, internal audit, corrective action, preventive action, safety checklist, quality control, management review and external assessment, both accreditation and proficiency testing. Management of risk also coincides with the management of safety in the medical laboratories, as exemplified by the safety audit checklists in ISO 15190.

Risk management is a planned, systematic process that is best implemented through a structured framework. This standard is intended to assist medical laboratories with the integration of risk management into their routine organization, operation and management.

Medical laboratories — Application of risk management to medical laboratories

1 Scope

This document specifies a process for a medical laboratory to identify and manage the risks to patients, laboratory workers and service providers that are associated with medical laboratory examinations. The process includes identifying, estimating, evaluating, controlling and monitoring the risks.

The requirements of this document are applicable to all aspects of the examinations and services of a medical laboratory, including the pre-examination and post-examination aspects, examinations, accurate transmission of test results into the electronic medical record and other technical and management processes described in ISO 15189.

This document does not specify acceptable levels of risk.

This document does not apply to risks from post-examination clinical decisions made by healthcare providers.

This document does not apply to the management of risks affecting medical laboratory enterprises that are addressed by ISO 31000, such as business, economic, legal, and regulatory risks.

2 Normative references

There are no normative references in this document.

koniec náhľadu – text ďalej pokračuje v platenej verzii STN